Lead Compound

Type: Keyphrase
Name: Lead Compound
First reported Aug 19 2014 - Updated Aug 20 2014 - 1 reports

Turning Car Batteries into Solar Cells

Lead has quite a history as the soft metal once saw many uses, such as water pipes to additives for gasoline and paint, but is now restricted to just a few, due to its potential health hazards. That is also why we see so many recycling programs specifically ... [Published Overclockers Club - Aug 19 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

Santhera Receives CHF 13.4 Million Through Sale of Treasury Shares

The treasury shares with a par value of CHF 1.00 were issued from the Company`s conditional capital. The newly issued shares represent 4.1% of the Company`s total outstanding share capital of CHF 4,911,728."This additional capital provides us with a strong ... [Published Pettinga Financial Advisors - Aug 15 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Lipocine: An Undervalued Biotech With An Approaching Catalyst

Summary Lipocine's Phase III results for its lead compound LPCN-1021 are expected to be announced in the third quarter of 2014. LPCN-1021 could be the first and only oral testosterone replacement therapy indicated for low testosterone in the U.S. LPCN-1021 ... [Published Seeking Alpha - Aug 13 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

Scientist invests in biotech stocks

Bjarke Krysel Christensen is a scientist with a specialization in microbiology (the study of microscopic organisms). He has invested in biotechnology stocks for more than two decades. Mr. Christensen’s investment approach is to use his scientific knowledge ... [Published Globe and Mail - Aug 08 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

Minerva Neurosciences Reports Second Quarter 2014 Financial Results

– Advanced Lead Compound MIN-101 in Phase 2 Studies for Schizophrenia and Clinical Development of MIN-202 in Insomnia –– Management to host conference call today at 4:30 p.m. ET –CAMBRIDGE, Mass., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, ... [Published EMoneyDaily - Aug 07 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Bristol-Myers Squibb Company v. Teva Pharmaceuticals USA, Inc.

Federal Circuit No. 2013-1306The Federal Circuit affirmed a judgment by the United States District Court for the District of Delaware invalidating clam 8 of U.S. Patent No. 5,206,244 (the '244 patent), owned by Bristol-Myers Squibb Co. ("BMS").Claim 8 ... [Published Lexology - Jul 30 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Rich Pharmaceuticals Hires Contract Research Organization to File NDA and Identify Clinical Trial Site(s) for Lead Compound

BEVERLY HILLS, Calif. -- Rich Pharmaceuticals, Inc. (OTCQB:RCHA) ("Rich" or the "Company") announced the company has hired San Diego, CA based contract research organization (CRO) Therinova Development, Inc., to file its new drug application (NDA), identify ... [Published Fierce CRO - Jul 28 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

RICH PHARMACEUTICALS : Hires Contract Research Organization to File NDA and Identify Clinical Trial Site(s) for Lead Compound

"We're aggressively pushing ahead with our AML Phase II clinical plans and with Therinova's clinical research expertise in oncology, we are confident in our regulatory approval strategy," said Ben Chang , CEO of Rich Pharmaceuticals, Inc.Therinova is ... [Published 4 Traders - Jul 24 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc.

Case Name: , 752 F.3d 967 (Fed. Cir. June 12, 2014) (Circuit Judges Prost, Plager, and Chen presiding; Opinion by Chen, J.) (Appeal from D. Del., Burke, M.J.)Drug Product and Patent(s)-in-Suit: Baraclude® (entecavir); U.S. Pat. No. 5,206,244 (“the ’244 ... [Published JD Supra - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Rich Pharmaceuticals Hires Contract Research Organization to File NDA and Identify Clinical Trial Site(s) for Lead Compound

(GLOBE NEWSWIRE) -- . (OTCQB:RCHA) ("Rich" or the "Company") announced the company has hired San Diego, CA based contract research organization (CRO) Therinova Development, Inc., to file its new drug application (NDA), identify and supervise Phase II ... [Published EMoneyDaily - Jul 23 2014]
First reported Jul 22 2014 - Updated Jul 23 2014 - 4 reports

SAGE Therapeutics Receives Fast Track Designation for Lead Compound SAGE-547 to Treat Status Epilepticus

(NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the SAGE-547 ... [Published Pettinga Financial Advisors - Jul 22 2014]
First reported Jul 16 2014 - Updated Jul 17 2014 - 2 reports

Adynxx Initiates Phase 2 Dose-Ranging Study of AYX1, Lead Compound for the Prevention of Post-Surgical Pain

SAN FRANCISCOThe 120-patient, placebo-controlled study will evaluate the safety and efficacy of two dose-volume levels of a single administration of AYX1 given prior to unilateral total knee replacement to reduce acute pain with movement and to prevent ... [Published Bio-Medicine - Jul 16 2014]

Quotes

"We have an early discovery with the tremendous potential to cure,” says Pankaj Desai, PhD, a professor of pharmacokinetics and drug metabolism at the UC James L Winkle College of Pharmacy who is leading the effort at UC to repurpose aromatase inhibitors, a class of drugs extensively used in the treatment of breast cancer in post-menopausal women."
"The intention of the EPO to grant this patent makes for an important addition to Progen's patent family. It complements the patents already granted for this patent family, and includes key jurisdictions such as the United States, Canada, Australia and Japan" said Jitto Arulampalam, Executive Chairman
"This is an important milestone for Cellceutix and for the field of infectious diseases," said Leo Ehrlich, the company's CEO. "There is no other antibiotic with these properties, which can treat infection and potentially decrease the burden of antibiotic resistance. Resistance, the antibiotic slayer. We are now in the process of manufacturing 30 kg of Brilacidin for future clinical trials which we plan for multiple forms of serious infections."
CEO Dr. Gary Wilcox stated, "We are pleased to report that we continue to move our drug candidates closer towards clinical development. By employing unique technologies and Nobel Prize winning expertise to drug discovery, we believe we have established a technology pipeline designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. We look forward to sharing future milestones with our stakeholders as they develop."

More Content

All (180) | News (108) | Reports (0) | Blogs (57) | Audio/Video (0) | Fact Sheets (1) | Press Releases (14)
sort by: Date | Relevance
UC Begins to Look at Breast Cancer Drugs to Tre... [Published University of Cincinnati - 4 hours ago]
European Patent Office Intention to Grant Sulfa... [Published Noodls - Aug 19 2014]
Turning Car Batteries into Solar Cells [Published Overclockers Club - Aug 19 2014]
Evaluation of Antimalarial Activity and Toxicit... [Published Plosone.org - Aug 19 2014]
Cellceutix Completes Enrollment in Phase 2b Cli... [Published Nasdaq - Aug 19 2014]
Cellceutix Completes Enrollment in Phase 2b Cli... [Published The CW11 - Aug 19 2014]
Cocrystal Pharma Reports Second Quarter Financi... [Published Yahoo! Finance - Aug 15 2014]
August 15, 2014: Santhera Receives CHF 13.4 Mil... [Published Noodls - Aug 15 2014]
Santhera Receives CHF 13.4 Million Through Sale... [Published Pettinga Financial Advisors - Aug 15 2014]
Santhera Receives CHF 13.4 Million Through Sale... [Published SPi World News - Aug 15 2014]
Santhera Receives CHF 13.4 Million Through Sale... [Published Franklin Credit Management Corporation - Aug 15 2014]
FDA Approval of Ceritinib for the Treatment of ... [Published The ASCO Post - Aug 15 2014]
Arno Therapeutics Reports Second Quarter 2014 F... [Published Town Hall - Aug 14 2014]
Conatus Pharmaceuticals' (CNAT) CEO Steven Ment... [Published Seeking Alpha - Aug 14 2014]
Conatus Pharmaceuticals Reports Second Quarter ... [Published Virtual Strategy Magazine - Aug 13 2014]
Conatus Pharmaceuticals Reports Second Quarter ... [Published CW Atlanta - Aug 13 2014]
$4.1M in NIAID funding should carry BioCryst’s ... [Published MedCity News - Aug 13 2014]
Durham’s BioCryst awarded $4.1M to research Ebo... [Published Raleigh News & Observer - Aug 13 2014]
CureDuchenne Extends Prosensa Pipeline Collabor... [Published Forbes.com - Aug 13 2014]
Lipocine: An Undervalued Biotech With An Approa... [Published Seeking Alpha - Aug 13 2014]
Becoming a master of the domain [Published Drug Discovery News - Aug 12 2014]
Threshold for success [Published Drug Discovery News - Aug 12 2014]
Phosphatidic acid promotes remyelination [Published Multiple Sclerosis Research - Aug 12 2014]
New Amsterdam Sciences: NAS911 Being Studied fo... [Published Individual.com - Aug 12 2014]
REG-AB Science: Clarification concerning the Fr... [Published Reuters - Aug 11 2014]
Globe says scientist bets big on Resverlogix [Published Stockwatch - Aug 11 2014]
Oncology combination drug discovery in the geno... [Published pharmaphorum - Aug 11 2014]
PTC Therapeutics' (PTCT) CEO Stuart Peltz on Q2... [Published Seeking Alpha - Aug 10 2014]
Scientist invests in biotech stocks [Published Globe and Mail - Aug 08 2014]
Anacor Pharmaceuticals' (ANAC) CEO Paul Berns o... [Published Seeking Alpha - Aug 08 2014]
1 2 3 4 5 6
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Phosphatidic acid promotes remyelination [Published Multiple Sclerosis Research - Aug 12 2014]
Yamamoto S, Gotoh M, Kawamura Y, Yamashina K, Yagishita S, Awaji T, Tanaka M, Maruyama K, Murakami-Murofushi K, Yoshikawa K. Cyclic phosphatidic acid treatment suppress cuprizone-induced demyelination and motor dysfunction in mice. Eur J Pharmacol. 2014. ...
SAGE Therapeutics Receives Fast Track Designati... [Published EON Science - Jul 22 2014]
CAMBRIDGE, Mass.--(EON: Enhanced Online News)--SAGE Therapeutics (NASDAQ: SAGE) announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the SAGE-547 development program to treat status epilepticus. ...
SAGE Therapeutics Receives Fast Track Designati... [Published Business Wire Science: Science News - Jul 22 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--SAGE Therapeutics (NASDAQ: SAGE) announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the SAGE-547 development program to treat status epilepticus. ...
SAGE Therapeutics Receives Fast Track Designati... [Published Business Wire Health News - Jul 22 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--SAGE Therapeutics (NASDAQ: SAGE) announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the SAGE-547 development program to treat status epilepticus. ...
Resolve Initiates Phase 2 Clinical Study in SLE [Published PR Newswire: Health - Jul 16 2014]
SEATTLE, July 16, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of a multi-dose, one month phase 2 clinical study with its lead compound RSLV-132 in systemic lupus erythematosus (SLE). Following the successful completion ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Rich Pharmaceuticals Hires Contract Research Or... [Published GlobeNewswire: Advertising News - Jul 23 2014]
Nora Therapeutics Presents Phase 1 Data on NT10... [Published GlobeNewswire: Advertising News - Jun 30 2014]
Cara Therapeutics Announces Appointment of Robe... [Published GlobeNewswire: Advertising News - Jun 24 2014]
Flexion Therapeutics Announces Positive Topline... [Published GlobeNewswire: Acquisitions News - Jun 17 2014]
TetraLogic Pharmaceuticals Announces Conference... [Published GlobeNewswire: Advertising News - Jun 13 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.